Accelerated Continue Theta-burst Stimulation (acTBS)Treatment for Obsessive Compulsive Disease

Last updated: April 12, 2023
Sponsor: Anhui Medical University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Obsessive-compulsive Disorder

Mood Disorders

Anxiety Disorders

Treatment

N/A

Clinical Study ID

NCT05221632
precise high-dose OCD
  • Ages 18-45
  • All Genders

Study Summary

The therapeutic effects of high-dose accelerated continue theta-burst stimulation (acTBS) and 1-Hz repetitive transcranial magnetic stimulation (rTMS) on obsessive-compulsive disorder (OCD) and its neural mechanism were investigated by functional MRI.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Clinical diagnosis of obsessive-compulsive disorder
  • Voluntarily participated and cooperated with the experiment.

Exclusion

Exclusion Criteria:

  • History of significant head trauma or neurological disorders.
  • Alcohol or drug abuse.
  • Organic brain defects on T1 or T2 images.
  • History of seizures or unexplained loss of consciousness.
  • Family history of medication refractory epilepsy.
  • Recent aggression or other forms of behavioral dyscontrol.

Study Design

Total Participants: 60
Study Start date:
March 01, 2021
Estimated Completion Date:
July 01, 2023

Study Description

All patients underwent a medical evaluation that included physical examination and routine laboratory studies before and after transcranial magnetic stimulation (rTMS) treatment. Patients were randomly allocated to 1-Hz rTMS group，acTBS group and sham group. Patients ware allocated by random number. The decision to enroll a patient was always made prior to randomization. The 1-Hz rTMS group received one round of stimulation every day for 30 minutes with a total stimulation of 1800 pulses for 5 consecutive days. Patients in the acTBS group received 10 two-minute rounds of stimulation each day, spaced 50 minutes apart, with a total of 18,000 pulses for five days.

Before the TMS treatment, Y-BOCS, Obsessions Symptom Scale revised (OCI-R), Hamilton Depression Scale (HAMD-17) and Hamilton Anxiety Scale (HAMA-14) were obtained by a trained investigator to assess baseline severity and other symptoms. The patients had receiving a battery measure of neuropsychological tests (standardized tests to investigate their cognitive problems, anxiety and depressive symptoms in daily life), magnetic resonance imaging scan in multimodalities。

After the last treatment, Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), OCI-R, HAMD-17 and HAMA-14 were obtained, as well as the Global Index of Safety to assess adverse events of the treatment. Patients were instructed to focus their answers on the past 5 days.The patients had also receiving a battery measure of neuropsychological tests and magnetic resonance imaging scan in multimodalities.

Participants were interviewed for two and four weeks after their last treatment to obtain a Y-BOCS score, and they were asked to focus their answers on the past week.

Connect with a study center

  • Anhui Medical University

    Hefei, Anhui 230032
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.